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Background Metabolomics, the identification and quantification of all metabolites in a biological 
system, is considered as a promising technique for biomarker discovery and mechanism elucidation. 
Chronic diseases occur at an elevated frequency in people with suboptimal health status (SHS). 
The recognition of SHS plays a significant role in the preventive, predictive and personalisded 
medicine (PPPM) of chronic diseases. Although a subjective screening tool for SHS has been 
developed, the objective biomarkers that give a better understanding of the pathophysiology of SHS 
warrant further investigation.  
Methods To report the original observations on the metabolomic feature of SHS, a liquid 
chromatography-mass spectrometry-based untargeted metabolomics analysis was conducted on 
plasma samples collected from 100 partciapnts (50 with SHS and 50 age- and sex-matched healthy 
controls).  
Results After controlling for the confounding factors (smoking, drinking, low-density lipoprotein 
cholesterol level, sleep duration, insomnia, anxiety, depression, and physical activity level) 24 
significantly differential metabolites were identified as the candidate biomarkers for SHS. Pathway 
analysis revealed that 1) sphingolipid metabolism, 2) taurine metabolism, and 3) steroid hormone 
biosynthesis are the disturbed metabolic pathways related to SHS. Protein-metabolite-disease 
network analysis showed that 148 proteins ? associated with 13 potential metabolic moelculaes for 
SHS, which could be potiential biomarkers for 17 typs of chornic diseases. A classification model 
was constructed based on the 24 candidate biomarkers, and the model yielded a sensitivity of 94.0%, 
a specificity of 90.0%, and an AUC of 0.977 (95% CI: 0.955 - 0.998, P < 0.001).  
Conclusion These findings support that plasma metabolomics could be used as an objectively 
diagnostic tool for SHS. Metabolic biosignature of SHS warrants further research in a larger 
population and the applications of SHS in PPPM practice. 
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Introduction 
Suboptimal health status (SHS) is a physical state between health and disease characterized 
by the perception of health complaints, chronic fatigue, and a constellation of physical symptoms 
lasting for at least three months (1, 2). It is recognized as a subclinical, reversible stage of chronic 
disease (3). Many health problems, such as psychosocial stress (4), cardiovascular risk factors (5, 
6), and type 2 diabetes mellitus (T2DM) (7) occur at an elevated frequency in people with SHS. The 
recognition of SHS plays a significant role in the prevention of chronic disease from the perspective 
of predictive, preventive and personalized medicine (PPPM) (3).  
Based on the perceived health complaints affected by SHS, a subjective screening tool for SHS, 
suboptimal health status questionnaire-25 (SHSQ-25), has been developed and validated in African,  
Asian and Caucasian ethnic groups (6-9). The SHSQ-25 includes 25 items encompassing five 
domains: fatigue, the cardiovascular system, the respiratory system, the immune system and mental 
status (2). A preliminary diagnostic criterion(score?)  for SHS (SHSQ-25 score ≥ 35) has also been 
recommended (10, 11). In order to understand the pathophysiology of SHS, several objective 
biomarkers, including cortisol, adrenaline, and noradrenaline, have been investigated (4, 12). 
Although previous studies have indicated that chronic psychosocial stress is associated with SHS, 
the underlying mechanisms of SHS remain partially understood. 
Metabolites are the small molecules of metabolism that drive essential cellular functions, such 
as energy production and storage, apoptosis and signal transduction (13). Metabolomics is an 
emerging “omics” tool involving the identification and quantification of all endogenous and 
exogenous metabolites in tissues, cells, and biofluids (14). It provides a snapshot of functional status 
of a biological system. Metabolomics has several advantages for the diagnosis of complex chronic 
disease. First, metabolites are the intermediate or end products of metabolism, which reflects what 
has been encoded by the genome and modified by environmental changes. Therefore, the levels of 
metabolites could be regarded as the ultimate response of biological systems to both genetic and 
environmental factors (15). Second, metabolome, which is connected with genome, transcriptome 
and proteome, represents the most downstream stage in the dynamic system of cellular processes. 
Metabolites are therefore easier to correlate with phenotype (16). In addition, because metabolomics 
provides downstream information of underlying biological pathways, the results can provide 
directions to develop treatments for disease (17). Given these advantages, the metabolome has 
become widely accepted as the dynamic and sensitive measures of the phenotype at the molecular 
level, and the metabolomics is at the forefront of biomarker and mechanism discovery. 
The main methodologies of metabolomics research are typically categorized as targeted 
metabolomics and untargeted metabolomics. Target metabolomics, which focuses on identifying 
and quantifying a predefined set of metabolites based on a priori information, is usually hypothesis-
driven. In the targeted approach, the chemical properties of the investigated metabolites are known, 
and methods are optimized for the analysis of specific metabolites and metabolic pathways of 
interest. By contrast, untargeted metabolomics aims to measure as many metabolites as possible 
from biological samples without a priori knowledge. The major advantage of untargeted 
metabolomics is the discovery of novel metabolites in relation to the study context, and it is therefore 
considered as hypothesis-generating method. Although untargeted metabolomics can be performed 
using nuclear magnetic resonance (NMR),  gas chromatography-mass spectrometry (GC-MS), or  
liquid chromatography-mass spectrometry (LC-MS) technologies, LC-MSenables to detect the 
broadest range of metabolites in a single analysis and therefore has been technique for metabolite 
profiling. LC-MS-based metabolomics has been applied in various research areas including 
biomarker discovery (18), precision medicine (15, 19), drug discovery (17), and systems biology 
(20).  
The aims of this study were to describe comprehensive metabolomic biosignature for SHS, and 
screen objectively metabolic biomarkers for SHS using LC-MS-based untargeted metabolomics. In 
addition, we investigated the metabolic pathways and the protein-metabolite-disease interaction 
network of the potential metabolite biomarkers to further understand the biological processes 
involved in SHS, which may prove to be useful for PPPM of chronic disease. 
 
Materials and Methods 
Study design and participants 
A population-based case-control study was conducted in a Chinese Han population who 
received routine health check-up at the student health centre of Weifang University between 
September 2017 and November 2017. In order to minimize the influence of age on metabolomics, 
the source population was undergraduate students aged 18 to 20 who were living in the university 
dormitory. 
All participants were required to meet the following inclusion criteria: (1) Chinese Han 
individuals; (2) aged 18 years or older; and (3) Shandong province native residents. Participants 
were excluded from the study if they met any of the following criteria: (1) history of somatic and 
psychiatric abnormalities; (2) intake of medication or supplements during the past three month; (3) 
history of any diseases involving the cardiovascular and cerebrovascular system, respiratory system, 
genitourinary system, digestive system, immune system and hematic system; (4) history of any 
surgeries or (5) pregnant or lactating women. 
Figure 1 shows the flow of potential participants through the study. ??? participants were asked 
to complete SHSQ-25 questionnaires at two time points of baseline and three? Months later, and 
participants with SHSQ-25 score ≥ 35 in both two surveys were selected as cases. Then, age- and 
sex-matched healthy participants with SHSQ-25 score < 35 in both two surveys were selected as 
controls. In total, the case group comprised 50 participants with SHS and the control group 
comprised 50 healthy participants without SHS were selected for blood biochemistry assays and 
LC-MS analysis . 
This study was approved by the Ethics Committee of the Weifang University, Weifang, China. 
Written informed consent was obtained from each participant at the beginning of the study. The 
ethics approval was given in compliance with the Declaration of Helsinki. 
 
Covariates 
Demographic characteristics of participants, including age, sex, marital status, and ethnicity, 
were collected by questionnaires. Lifestyle information on smoking, drinking, and sleep duration 
were also collected. Participants were assigned to be non-smokers (never regularly smoked daily) 
or smokers (former smoker or current smoker) according to their smoking status. Drinking status 
was classified as non-drinker, light to moderate drinker, or heavy drinker according to the 2015-2020 
Dietary Guidelines for Americans (21). 
Anthropometric measurements were carried out by trained nurses and physicians. Height, 
weight, waist circumference (WC) and hip circumference (HC) were measured with the participants 
wearing only indoor clothing and without shoes. Body mass index (BMI) was calculated as weight 
in kilograms divided by height in metres squared (kg/m2). Waist-to-hip ratio (WHR) was calculated 
as WC in centimetres divided by HC in centimetres. Systolic blood pressure (SBP) and diastolic 
blood pressure (DBP) were measured twice on the right arm using a standard mercury 
sphygmomanometer with the participants resting for at least 10 minutes in a sitting position. 
The blood biochemistry assays included measurements of the levels of fasting plasma glucose 
(FPG), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL), low-
density lipoprotein cholesterol (LDL), uric acid (UA), creatinine, blood urea nitrogen (BUN), alanine 
transaminase (ALT), aspartate transaminase (AST), creatine kinase-MB (CK-MB), lactate 
dehydrogenase (LDH), and alkaline phosphatase (ALP). 
The levels of physical activity were measured using the long form of the International Physical 
Activity Questionnaire (IPAQ) and classified as low, moderate and high levels according to the 
protocol for IPAQ (22). The measurements of insomnia, anxiety, and depression were assessed 
using the Athens Insomnia Scale (23), the Hamilton Anxiety Rating Scale (24), and the Hamilton 
Depression Rating Scale (25), respectively. 
 
Plasma collection and metabolomics analysis 
Fasting blood samples were collected by venipuncture in the morning after an overnight fasting. 
The plasma samples were then separated in the laboratory after centrifugation at 3000 rpm for 10 
minutes and immediately stored at -80°C until metabolomics analysis. 
Plasma samples were thawed and proteins were precipitated by adding 300 μL of cold methanol 
to 100 μL of plasma. The mixture was then centrifuged at 12,000 rpm for 15 min at 4 °C and 200 μL 
of supernatant was transferred into polypropylene tubes for further analyses. To assess the stability 
and reproducibility of LC-MS analyses, a quality control (QC) sample was prepared by mixing equal 
volumes (10 μL) of the collected 100 plasma samples. The QC sample was also subjected to similar 
protein precipitation procedure and seven aliquots of QC sample were injected during LC-MS 
analyses. 
LC-MS analysis was performed using an LC-MS system consisting of an UltiMate 3000 liquid 
chromatography system (Thermo Fisher Scientific Waltham, USA) coupled with an Orbitrap Elite 
mass spectrometer (Thermo Fisher Scientific Waltham, USA). A 4 μL aliquot of each sample was 
injected onto a C18 column (100 x 4.6 mm, 3 μm) with the column temperature maintained at 40 °C. 
The flow rate was 0.3 mL/min, and the mobile phase consisted of ultrapure water with 0.1% (v/v) 
formic acid (A) and acetonitrile with 0.1% (v/v) formic acid (B). The gradient of the mobile phase is 
shown in Supplementary Table 1.  
The column eluent was directed to the MS and full-scan profiling data were acquired in the 
Obitrap mass analyser with the scan range of 50-1000 mass-to-charge ratio (m/z) in both positive 
and negative ion mode. The source ion parameters applied were as follows: heater temperature of 
300 °C, sheath gas flow rate of 45 arbitrary units, auxiliary gas flow rate of 15 arbitrary units, sweep 
gas flow rate of 1 arbitrary units, capillary temperature of 350 °C, spray voltage of 3 kV (positive ion 
mode) and 3.2 kV (negative ion mode). 
 
Statistical analysis 
The acquired mass spectrometry data were converted into .mzXML format by using 
ProteoWizard msConvert (26). The XCMS online was applied for pre-processing of raw 
metabolomics data, including feature detection, retention time correction and alignment (27). The 
80% rule was used to treat the missing values, then a list including m/z, retention time and peak 
intensity was generated.  
Normality distribution of all variables were tested by the Shapiro-Wilk test. Normally distributed 
continuous variables were reported as mean ± standard deviation (SD), and non-normally 
distributed continuous variables were represented as medians and interquartile ranges (IQR). 
Categorical variables were represented as frequencies and percentages. The differences in 
categorical variables between the two groups were tested by Chi-square test or Fisher’s exact test. 
The differences in continuous variables between the two groups were tested by Student t-test or 
Mann-Whitney U test. The Benjamini-Hochberg method was used to perform the multiple testing 
corrections and false discovery rate (FDR) was set to 0.05. The principal component analysis (PCA) 
was used to provide an informative summary of the metabolomics dataset and relationships 
between groups. To identify the metabolites responsible for the discrimination, the orthogonal partial 
least squares projection-discriminant analysis (OPLS-DA) model was performed by using SIMCA 
14.1 software (Umetrics, Umea, Sweden). Open source databases, including Kyoto Encyclopedia 
of Genes and Genomes (KEGG) (28), Human Metabolome Database (HMDB) (29), METLIN (30), 
and PubChem (31) were used to identify the metabolites and metabolic pathways. Correlation 
analysis was performed to estimate the association between identified metabolites by Spearman’s 
rank correlation method and correlation coefficients were shown in plot (R package “corrplot”). A 
protein-metabolite-disease interaction network was created by using MetaboAnalyst (32) based on 
information gathered from HMDB (29) and Search Tool for Interactions of Chemicals (STITCH) 
database (33), and the Cytoscape software 3.7.1 (National Institute of General Medical Sciences, 
Bethesda, USA) was used to plot the interaction networks. Multivariate binary logistic regression 
was used to construct classification models for SHS. Receiver operating characteristic (ROC) curves 
and the area under the curve (AUC) were used to assess the classification performance of the 
models.  
Data analysis was performed using SPSS 25.0 (IBM Corporation, New York, USA) and R 3.4.3 
(34). All reported P values were two-tailed, and P < 0.05 was considered statistically significant. 
 
Results 
Characteristics of participants 
In total, 50 participants with SHS and 50 age- amnd sex-matched healthy controls without SHS 
were included in this study. The demographic, anthropometric and biochemical characteristics of 
participants are described in Table 1. The average ages of SHS and control groups were 19.00 ± 
0.73 and 18.98 ± 0.65 years respectively, with the same age range of 18.00 - 20.00 years. The level 
of LDL and sleep duration in the SHS group was significantly lower than those in the control group, 
whereas higher SHS, insomnia, anxiety, and depression scores were observed in the SHS group (P 
< 0.05). In terms of other characteristics, there were no statistically significant differences observed 
between the two groups (P > 0.05). 
 
Discovery and identification of potential metabolic biomarkers 
LC-MS technique was used to performed metabolomics analysis on 100 plasma samples and 
7 QC samples, and the total ion chromatograms of these samples are presented in Supplementary 
Figure 1. PCA plots were performed to show the within-group and between-group variations 
(Supplementary Figure 2). After feature detection, retention time correction, alignment, and removal 
of missing values, 4399 features were detected in positive ion mode and 1976 features were 
detected in negative ion mode (Supplementary Table 2).  
The OPLS-DA model was used to calculate the variable importance on projection (VIP) values 
of each feature, and features with VIP values > 1 were considered the potential differential 
metabolites. The OPLS-DA score plot showed that the SHS group was obviously separated from 
the control group, indicating that the levels of metabolites in SHS participants  are different from 
the controls (Figure 2). The cumulative R2Y and cumulative Q2 values of OPLS-DA model were 
calculated to estimate the “goodness of fit” and the ability of prediction of the model. The OPLS-DA 
model yielded a cumulative R2Y of 0.858 and a cumulative Q2 of 0.646. 
Among 6375 detected features, 225 detected features with VIP values > 1, P values < 0.05, 
FDR adjusted P values < 0.05, and fold change > 1.2 (or < 0.83) were selected as the candidate 
features for SHS (Supplementary Table 2). Then the m/z values and retention times of these features 
were used to identified potential differential metabolites, and 26 of the 255 differential features were 
identified successfully (Table 2). After adjusting for the confounding factors, including smoking, 
drinking, LDL, sleep duration, insomnia score, anxiety score, depression score, and physical activity 
level, 24 significantly differential metabolites between the SHS group and the control group were 
finally selected as the candidate biomarkers for SHS (Table 2). Among these 24 metabolites, 12 
metabolites in SHS participants were significantly higher than those in controls, whereas lower 
levers of 12 metabolites were found in SHS participants. A heat map was performed to visualize the 
relative quantities of 24 metabolites, which indicated significant differences in metabolites between 
SHS group and control group (Figure 3).   
 
Pathway analysis of potential metabolic biomarkers 
In order to reveal the disturbed metabolic pathways related to SHS, the pathway analysis of 24 
candidate metabolites was performed using Metaboanalyst. As shown in Figure 4, these metabolites 
were involved in 12 metabolic pathways ( Supplementary Table 3). Among these 12 metabolic 
pathways, three pathways with P values < 0.05 and impact values > 0.00 were identified as 
sphingolipid metabolism, taurine metabolism, and steroid hormone biosynthesis pathways, 
respectively. Sphinganine 1-phosphate, sphinganine, sphingosine, sphingomyelin are involved in 
the sphingolipid metabolism. Acetyl phosphate and glutaurine are metabolites participated in the 
taurine and hypotaurine metabolism. Androstenedione, progesterone, and pregnanolone are 
involved in the steroid hormone biosynthesis.  
    
Correlation analysis of potential metabolic biomarkers 
To investigate the potential relationships of the 24 differential metabolites, the Spearman’s 
correlation coefficients between the metabolites were calculated based on the levels of metabolites 
(Supplementary Table 4). A correlation plot was performed to visualize the correlation coefficients of 
24 metabolites in Figure 5. In terms of the metabolites in sphingolipid metabolism pathway, the level 
of sphinganine was positively correlated with the level of sphingosine (r = 0.975, P < 0.001), and 
negatively correlated with the levels of sphinganine 1-phosphate (r = -0.713, P < 0.001) and 
sphingomyelin (r = -0.468, P < 0.001). No correlation was observed between the levels of acetyl 
phosphate and glutaurine (r = -0.026, P = 0.794) in the taurine and hypotaurine metabolism pathway. 
The level of androstenedione was positively correlated with the level of progesterone (r = 0.856, P 
< 0.001), whereas a negative correlation was found between the levels of androstenedione and 
pregnanolone (r = -0.323, P = 0.001) in the steroid hormone biosynthesis pathway. 
 
Protein-metabolite-disease network of potential metabolic biomarkers 
In order to provide a comprehensive view of potential functional relationships between potential 
metabolic biomarkers, proteins, and diseases, a protein-metabolite-disease interaction network was 
conducted based on the information searched from HMDB and STITCH databases. Finally, 13 
candidate metabolites associated with 148 proteins which were correlatied ? with 17 diseases  
pheno types (Figure 6). Progesterone and androstenedione in the steroid hormone biosynthesis 
pathway are associated with three diseases, including adrenal hyperplasia, adrenal insufficiency, 
and schizophrenia. Pregnanolone and progesterone are associated with major depressive disorder. 
Androstenedione is  associated with rheumatoid arthritis and polycystic ovary syndrome 1.  
 
Metabolite profiling as an objective diagnostic test for SHS 
To improve the classification accuracy of candidate metabolites for SHS, a logistic regression 
analysis was performed to construct a classification model based on 24 significantly differential 
candidate metabolites. Metabolomics dataset was standardized before logistic regression analysis 
and the step-wise method was used to select the best classification model. The classification model 
based on candidate metabolites was as follows: 
Logit (p = SHS) = -2.536 - 6.638 × (Sphingosine) + 1.156 × (Pregnanolone) + 1.929 × 
(Taurolithocholate sulfate) + 1.432 × (Cervonyl carnitine) 
ROC curve and the AUC were used to assess the diagnostic performance of the model. The 
model yielded a sensitivity of 94.0%, a specificity of 90.0%, and an AUC of 0.977 (95% Confidence 
Interval (CI): 0.955-0.998, P < 0.001) (Figure 7). 
 
Discussion 
Previous studies showed that untargeted metabolomics based on LC-MS is a promising high-
throughput approach for biomarker discovery. In this study, we described a comprehensive 
matabolomic feature of SHS and the metabolic phenotypes revealed significant differences between 
individuals with SHS and individuals with ideal health status. With 24 significantly altered metabolites 
in plasma samples, the pathway analysis suggested that three pathways (?????? Speciciy ???) 
were disturbed in individuals with SHS. ROC curve analysis showed that combination of metabolic 
biomarkers can distinguish individuals with SHS from individuals with ideal health status with a 
sensitivity of 94.0%, a specificity of 90.0%, and an AUC of 0.977. To the best of our knowledge, this 
study is the first metabolomics study of SHS. 
It is believed that SHS is an early stage of chronic disease >?, and reliable methods for the 
identification of the individuals with SHS are of great importance for PPPM of chronic disease (3). 
In the present study, SHSQ-25 was applied in a population of 2861 participants to assess their SHS 
scores at baseline. After follow-up for 3 months, we assessed their SHS scores for the second time. 
The aim of this design was to minimize the influence of subjective factors on SHS scores and to 
give each participant an SHS score  at a longgidutial time frame. On the other hand, the 3-month 
follow-up also can define an individual who has been a state of prolonged, profound suboptimal 
health. The potential confounding factors, including age, sex, smoking, drinking, level of LDL, sleep 
duration, level of physical activity, insomnia, anxiety, and depression, were also investigated and 
adjusted in this study. 
Sphingolipids are a class of bioactive lipids, which are key modulators of several physiologic 
and pathophysiologic processes, such as cell cycle, apoptosis, stress and inflammatory responses 
(35). Sphingolipid metabolism pathway is highly interconnected and branched, and the 
misregulation of one sphingolipid enzyme may lead to accumulation or depletion of one or more 
species of sphingolipids (36),. A umique (abnormal?)  sphingolipid profile may result in a 
pathological condition triggered by accumulation of sphingolipids (37). In this study, the levels of 
sphingomyelin and sphinganine 1-phosphate in individuals with SHS were significantly higher than 
those in healthy controls, whereas lower levels of sphingosine and sphinganine were found in 
individuals with SHS. Our findings indicate that one or more sphingolipid enzymes may be 
misregulated in individuals with SHS. Sphingomyelin is one of the main structural components of 
biological membranes (38), and the overexpression of sphingomyelin synthase increases 
cholesterol accumulation (39). Sphingomyelin plays an essential role in the formation of 
atherosclerotic lesions, and it is a risk factor for subclinical atherosclerosis and coronary artery 
disease (40, 41). Furthermore, our previous studies showed that SHS is associated with 
cardiovascular disease (5, 6). In the present study, the level of sphingomyelin is significantly higher 
in individuals with SHS, which strongly supports our idea that SHS is the subclinical stage of 
cardiovascular disease. 
Steroid hormones are the steroid that acts as hormones, and steroid hormones biosynthesis is 
the multi-step enzymatic conversion of cholesterol via intermediate steroid precursor into biological 
active steroid hormones (42). Steroid hormones are the key regulators of a diverse array of 
physiological processes, including the maintenance of carbohydrate metabolism, sodium and fluid 
homeostasis, development of secondary sex characteristics, and reproduction (43). This study 
observed lower levels of androstenedione and progesterone in individuals with SHS compared with 
individuals with ideal health status, whereas higher level of pregnanolone has been found in 
individuals with SHS. Our previous study also found that the level of cortisol, a steroid hormone, is 
elevated in plasma of individuals with SHS (4). These findings also indicate that hormonal disorders 
might play an important role in the pathophysiology of SHS. 
Taurine is one of the most abundant amino acids in the body and it can be synthesized from 
other amino acids such as methionine and cysteine (44). Taurine is involved in a wide range of 
biological processes, including antioxidant action, anti-inflammatory effect, glucose homeostasis 
and osmoregulation (45). In this study, acetyl phosphate and glutaurine, which involved in the taurine 
and hypotaurine metabolism, were identified as the metabolic biomarkers for SHS. The level of 
acetyl phosphate in participants with SHS is significantly lower than those in participants with ideal 
health status, whereas higher level of glutaurine was found in participants with SHS. These data 
proposed that taurine metabolism disorder is involved in the pathophysiology of SHS. 
The metabolite-protein interaction network enables exploration and visualization of interactions 
between functionally related metabolites and proteins. Based on the reactions from pathway 
databases, literature associations, similar structures, and similar activities, the interactions between 
metabolites and proteins were extracted from STITCH database (33). This network visualization can 
be used to gain novel insights into pathophysiology of SHS or assist with the development of new 
hypotheses for SHS research. According to the association obtained from HMDB database, 
metabolite-disease interaction network was also conducted to explore the disease-related 
metabolites. Several digestive system diseases, including cholestasis (46), Crohn’s disease (47) 
and bile acid synthesis defect (48), were found to be associated with bilirubin metabolism disorder. 
In this study, increased level of bilirubin was observed in the individuals with SHS, which indicates 
that bilirubin metabolism disorder might associate with the SHS phonetype of the digestive system 
symptoms, such as nausea and poor appetite. Previous studies reported that several mental 
disorders, including major depressive disorder (49) and schizophrenia (50), were associated with 
progesterone metabolism disorder. The higher level of progesterone in individuals with SHS 
indicated that progesterone metabolism disorder is associated with that mental symptom of SHS. 
The metabolite-disease interaction network might assist with the discovery of functional connections 
between SHS and diseases in this network. 
Several limitations in this study are noteworthy. First, because our study is a case-control study 
with a relatively small sample size, the universality of these findings could be questioned. However, 
the longitudial design ……….  In addition, considering the semi-quantitative nature of the 
untargeted metabolomics method, a targeted metabolomics study is underway against the same 
cohort to validate the putative biomarkers and pathways based on the findings in this study. Finally, 
although we attempted to control as many potential confounders as possible, the dietary information ? 
was not collected due to the complexity of dietary survey. Despite the limitations, this study has 
provided a new idea that plasma metabolomics might offer a novel alternative for the recognition of 
SHS. Building on the present findings, further studies of larger cohorts from diverse geographical 
areas and populations with different age ranges are warranted. 
 
Conclusions 
Individuals with SHS may involve a universal metabolic disturbance. SHS has a biosignature 
that can be identified using untargeted metabolomics technique. Three metabolic pathway 
disturbances are related to SHS and 24 significantly differential metabolites could be used as the 
candidate biomarkers for SHS. The combination of metabolic biomarkers offered excellent 
diagnostic performance for distinguishing individuals with SHS from individuals with ideal health 
status. The finding of an objective biosignature in SHS will give us better understanding of the 
etiology and pathophysiology of SHS, and help clinicians recognize individuals with higher risk of 
chronic disease from the perspective of predictive, preventive and personalized medicine. 
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LDL = low-density lipoprotein cholesterol 
UA = uric acid 
BUN = blood urea nitrogen 
ALT = alanine transaminase 
AST = aspartate transaminase 
CK-MB = creatine kinase-MB 
LDH = lactate dehydrogenase 
ALP = alkaline phosphatase 
IPAQ = International Physical Activity Questionnaire 
QC = quality control 
m/z = mass-to-change ratio 
SD = standard deviation 
IQR = interquartile ranges 
FDR = false discovery rate 
PCA = principal component analysis 
OPLS-DA = orthogonal partial least squares projection-discriminant analysis 
KEGG = Kyoto Encyclopedia of Genes and Genomes 
HMDB = Human Metabolome Database 
ROC = Receiver operating characteristic 
AUC = area under the curve 
VIP = variable importance on projection 
CI = confidence interval 
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Figure 1. Study population flow chart 
 
Table 1. Characteristics of the study participants 
Characteristics Control Group SHS Group P value 
N 50.00 50.00  
Sex   1.000 
  Male 10.00 (20.00%) 10.00 (20.00%)  
  Female 40.00 (80.00%) 40.00 (80.00%)  
Age (years) 19.00 (19.00 - 19.00) 19.00 (18.00 - 20.00) 0.888 
Smoking   1.000 
    Non-smoker 47.00 (94.00%) 47.00 (94.00%)  
    Smokers 3.00 (6.00%) 3.00 (6.00%)  
Drinking   0.695 
    Non-drinker 46.00 (92.00%) 44.00 (88.00%)  
    Light to moderate drinker 1.00 (2.00%) 3.00 (6.00%)  
    Heavy drinker 3.00 (6.00%) 3.00 (6.00%)  
Dietary   1.000 
    Omnivore 50.00 (100.00%) 50.00 (100.00%)  
    Vegetarian 0.00 (0.00%) 0.00 (0.00%)  
SBP (mmHg) 115.50 (109.00 - 124.50) 118.00 (111.75 - 126.25) 0.235 
DBP (mmHg) 74.86 ± 8.82 76.70 ± 9.95 0.330 
BMI (kg/m2) 21.41 (19.92 - 23.40) 21.26 (19.43 - 23.07) 0.442 
WC (cm) 71.01 ± 8.13 70.91 ± 8.09 0.951 
HC (cm) 92.03 ± 7.80 92.45 ± 6.76 0.774 
WHR 0.77 (0.74 - 0.80) 0.75 (0.72 - 0.80) 0.427 
FPG (mmol/L) 4.94 (4.78 - 5.14) 4.90 (4.75 - 5.09) 0.326 
TC (mmol/L) 4.22 ± 0.66 3.98 ± 0.63 0.066 
TG (mmol/L) 0.90 (0.80 - 1.10) 0.90 (0.70 - 1.00) 0.403 
HDL (mmol/L) 1.44 ± 0.27 1.48 ± 0.28 0.547 
LDL (mmol/L) 2.40 (2.00 - 2.90) 2.20 (1.90 - 2.50) 0.044 
UA (μmol/L) 317.50 (261.05 - 406.25) 308.85 (269.65 - 377.08) 0.788 
Cre (μmol/L) 59.55 (55.50 - 69.63) 58.95 (55.88 - 65.45) 0.674 
BUN (mmol/L) 3.95 (3.30 - 4.50) 4.15 (3.30 - 4.93) 0.446 
ALT (U/L) 12.65 (9.23 - 19.15) 13.30 (9.18 - 18.75) 0.852 
AST (U/L) 20.90 (17.90 - 24.18) 21.50 (17.78 - 25.10) 0.627 
CK-MB (U/L) 6.70 (5.28 - 8.55) 6.05 (5.18 - 7.33) 0.181 
LDH (U/L) 147.44 ± 24.09 143.09 ± 21.41 0.343 
ALP (U/L) 59.54 (50.12 - 75.72) 58.48 (51.71 - 72.44) 0.825 
Sleep duration (hours) 8.00 (7.00 - 8.00) 7.00 (7.00 - 8.00) 0.030 
SHS score (First survey) 12.00 (8.00 - 21.25) 40.00 (37.00 - 44.00) <0.001 
SHS score (Second survey) 16.00 (12.50 - 25.25) 35.00 (35.00 - 40.00) <0.001 
Insomnia score 3.00 (1.75 - 5.25) 6.50 (6.00 - 9.00) <0.001 
Anxiety score 2.00 (0.00 - 4.25) 9.00 (3.00 - 13.25) <0.001 
Depression score 2.00 (0.00 - 3.00) 5.00 (1.75 - 10.25) <0.001 
Physical activity   0.165 
    Moderate level 9.00 (18.00%) 16.00 (32.00%)  
    High level 41.00 (82.00%) 34.00 (68.00%)  
Note: Data are presented as means ± SD, medians (interquartile ranges) or frequencies (percentages). P < 0.05 is 
considered statistically significant. SHS, suboptimal health status; N, number of participants; SD, standard deviation; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; WC, waist circumference; HC, hip 
circumference; WHR, waist-to-hip ratio; FPG, fasting plasma glucose; TC, total cholesterol; TG, total triglycerides; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; UA, uric acid, Cre, creatinine; BUN, blood urea nitrogen; TBIL, 
total bilirubin; ALT, alanine transaminase; AST, aspartate transaminase; CK-MB, creatine kinase-MB; LDH, lactate 












Figure 2. Metabolic biomarkers for SHS 
Note: (A) The orthogonal projection to latent structure-discriminant analysis (OPLS-DS) score plots. (B) The disturbed metabolic 
pathways in suboptimal health status. (C) The diagnostic performance of potential metabolic metabolites for SHS.
Table 2. Differential metabolites identified between SHS participants and controls 
Metabolites Mode Observed m/z RT (min) Trend   FC  VIP value P Value *P Value #P value 
Acetyl phosphate Positive 139.9881 15.8044 Down 0.815 3.744 0.004 0.006 0.016 
Spermine Positive 202.2167 5.0300 Down 0.528 1.282 <0.001 <0.001 <0.001 
Androstenedione Positive 219.2154 4.2883 Down 0.472 1.034 <0.001 <0.001 <0.001 
Progesterone Positive 247.2463 4.9932 Down 0.113 2.707 <0.001 <0.001 0.004 
Glutaurine Positive 255.0659 4.3251 Up 1.774 1.038 <0.001 <0.001 0.001 
Glycerophosphocholine Positive 258.1109 0.9428 Up 1.451 1.959 <0.001 <0.001 <0.001 
Hexanoylcarnitine Positive 260.1864 4.0222 Down 0.735 1.395 <0.001 0.017 0.476 
L-Octanoylcarnitine Positive 288.2178 4.6330 Down 0.739 2.524 0.005 0.008 0.397 
Sphinganine 1-phosphate Positive 298.3109 12.1612 Up 2.524 1.783 <0.001 <0.001 <0.001 
Sphinganine Positive 302.3061 6.8676 Down 0.085 15.831 <0.001 <0.001 0.042 
Glyerophosphoinositol Positive 317.0612 4.9279 Up 1.220 1.616 <0.001 <0.001 0.001 
Sphingosine Positive 318.3008 5.9321 Down 0.139 8.451 <0.001 <0.001 0.003 
Pregnanolone Positive 319.2636 11.3965 Up 1.386 3.833 <0.001 <0.001 0.001 
2-Arachidonylglycerol Positive 343.2636 11.0523 Up 1.401 3.040 <0.001 <0.001 0.001 
4alpha-Methylzymosterol-4-carboxylate Positive 375.3669 7.8852 Down 0.119 2.330 <0.001 <0.001 0.015 
S-Adenosylhomocysteine Positive 403.1396 5.6208 Down 0.065 1.119 <0.001 <0.001 0.002 
Reduced Vitamin K Positive 403.3981 8.7993 Down 0.088 1.909 <0.001 <0.001 0.046 
7'-Carboxy-alpha-chromanol Positive 416.2160 6.4400 Down 0.516 3.595 <0.001 <0.001 0.001 
Taurolithocholate sulfate Positive 480.3092 8.0890 Up 1.241 2.064 0.005 0.008 0.042 
Cervonyl carnitine Positive 494.3251 7.2723 Up 1.202 4.716 <0.001 <0.001 0.001 
Hexacosanoyl carnitine Positive 512.5042 12.2543 Down 0.399 1.353 <0.001 <0.001 0.001 
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestanoate Positive 519.3287 7.0182 Up 1.340 1.576 <0.001 <0.001 0.005 
18-CoA-18-oxo-dinorleukotriene B4 Positive 542.1220 15.3080 Up 1.304 1.181 <0.001 <0.001 0.001 
Sphingomyelin Positive 703.5764 7.8690 Up 1.370 6.219 <0.001 <0.001 <0.001 
9'-Carboxy-gamma-chromanol Negative 374.2449 6.1306 Up 2.144 2.176 <0.001 <0.001 <0.001 
Bilirubin Negative 583.2558 4.9730 Down 0.723 1.769 0.001 0.001 0.032 
Note: m/z, mass-to charge ratio; RT, retention time; FC, fold chnage; VIP, variable importance on projection. Down trend, relatively lower levels of metabolites present in SHS group. Up trend, relatively 
higher levels of metabolites present in SHS group.   
P Value, P value from Student t-test without adjustment; *P Value, P value adjusted for false discovery rate using Benjamini-Hochberg method. #P Value, P value adjusted for smoking, drinking, low-
density lipoprotein cholesterol, sleep duration, insomnia score, anxiety score, depression scores, physical activity and false discovery rate; P < 0.05 is considered statistically significant. 
 




Figure 4. Correlation coefficients of 24 potential metabolic biomarkers for SHS 
Note: Statistically significant correlations between two metabolites are shown, while the insignificant correlation coefficients are blank in the boxes. 
The positive correlations are represented by blue color, while negative correlations are represented by red color. P < 0.05 is considered statistically 




Figure 5. The metabolite-gene-disease network analysis of potential metabolites for SHS 
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